Apricoxib: Difference between revisions

Apricoxib
Identifiers
	IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide;
CAS Number	162011-90-7;
PubChem CID	9820073;
ChemSpider	7995822;
UNII	5X5HB3VZ3Z;
KEGG	D08657;
CompTox Dashboard (EPA)	DTXSID60173502 ;
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.4387 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C;
	InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23); Key:JTMITOKKUMVWRT-UHFFFAOYSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 07:24, 23 February 2020

Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.^[1] Development was abandoned in 2015 due to poor clinical trial results.^[2]

References

^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

[1] Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.

[2] "Apricoxib". Adis Insight. Springer Nature Switzerland AG.

[1]

[2]

@@ Line 25: / Line 25: @@
 }}
-'''Apricoxib''' is an experimental anticancer drug. It is a [[COX-2 inhibitor]] which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{cite journal | doi = 10.1158/1078-0432.CCR-12-0453 | title=Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer | journal=Clinical Cancer Research | date=2012 | volume=18 | issue=18 | pages=5031–5042 | first=A. | last=Kirane | pmid=22829202 | pmc=3777527}}</ref> Development was abandoned in 2015 due to poor clinical trial results.<ref>http://adisinsight.springer.com/drugs/800026002</ref>
+'''Apricoxib''' is an experimental anticancer drug. It is a [[COX-2 inhibitor]] which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{cite journal | vauthors = Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA | display-authors = 6 | title = Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer | journal = Clinical Cancer Research | volume = 18 | issue = 18 | pages = 5031–42 | date = September 2012 | pmid = 22829202 | pmc = 3777527 | doi = 10.1158/1078-0432.CCR-12-0453 }}</ref> Development was abandoned in 2015 due to poor clinical trial results.<ref>{{cite web | title = Apricoxib | url = http://adisinsight.springer.com/drugs/800026002 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}</ref>
-==See also==
+== See also ==
 *[[Tilmacoxib]]
 *[[cimicoxib]]
@@ Line 33: / Line 33: @@
 *[[Celecoxib]]
-==References==
+== References ==
-{{Reflist|2}}
+{{Reflist}}
 {{Prostanoidergics}}
@@ Line 41: / Line 41: @@
 [[Category:Sulfonamides]]
 [[Category:Abandoned drugs]]
 {{musculoskeletal-drug-stub}}